-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2024-518473-34-00
5
2019-11-20
Multiple Myeloma
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
-
2023-505477-33-00
5
2019-06-18
Psoriatic Arthritis
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2023-506921-12-00
5
2018-12-27
ER+/HER2- Breast Cancer
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer
-
2024-516263-92-00
5
2018-06-25
Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney
-
2023-506429-13-00
5
2018-05-02
Progressive multiple sclerosis (PMS)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia